GW Pharmaceuticals has presented positive data on the safety and effectiveness of Epidiolex, recently approved by the U.S. Food and Drug Administration (FDA) to treat epileptic seizures in Dravet and Lennox-Gastaut syndromes, as well as the potential mechanisms behind its anti-epileptic properties.
The data were presented at the 13th Annual European Congress of Epileptology (ECE), held recently in Vienna, Austria.
GW Pharmaceuticals’ lead cannabinoid compound, Epidiolex, received FDA-approval in June for the treatment of seizures associated with both Dravet and Lennox-Gastaut syndromes, in patients ages 2 and older. These syndromes are rare and severe forms of childhood-onset epilepsy that are very difficult to treat.
In epilepsy, the endocannabinoid system — a collection of receptors, mainly in the brain, that are configured to accept only cannabinoids — is defective and can lead to seizures. Epidiolex is a purified form of cannabidiol (CBD), the most abundant non-psychoactive cannabinoid in the marijuana plant, that mimicks the natural